0001099910-24-000055.txt : 20240227 0001099910-24-000055.hdr.sgml : 20240227 20240125151955 ACCESSION NUMBER: 0001099910-24-000055 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKANDA CORP. CENTRAL INDEX KEY: 0001888014 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1A, 1B LEAROYD ROAD CITY: NEW ROMNEY STATE: X0 ZIP: TN28 8XU BUSINESS PHONE: 442034889514 MAIL ADDRESS: STREET 1: 77 KING STREET WEST, SUITE 400 STREET 2: C/O DENTONS CANADA LLP CITY: TORONTO STATE: A6 ZIP: M5K 0A1 CORRESP 1 filename1.htm

AKANDA CORP.

1a, 1b Learoyd Road
New Romney TN28 8XU

United Kingdom

January 25, 2024

SUBMISSION VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, NE

Washington, DC 20549

Attn:

Ms. Doris Stacey Gama

	Re:	Akanda Corp.
		Registration Statement on Form F-3
		Filed January 18, 2024
		File No. 333-276577

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akanda Corp. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement to January 29, 4:00 p.m., Eastern Time, or as soon thereafter as is reasonably practicable.

Thank you for your assistance in processing this filing. Should you have any questions or comments regarding this matter, please do not hesitate to contact the Company’s counsel, Mr. Mark C. Lee at (916) 603-3444.

		Sincerely,


	By:	/s/ Katie Field
		Katie Field
		Interim Chief Executive Officer and Director

cc:	Mark C. Lee, Esq., Rimon, P.C.